实用癌症杂志
實用癌癥雜誌
실용암증잡지
THE PRACTICAL JOURNAL OF CANCER
2015年
1期
17-19,24
,共4页
人附睾蛋白HE4%CA125抗原%恶性卵巢癌%卵巢恶性肿瘤风险模型
人附睪蛋白HE4%CA125抗原%噁性卵巢癌%卵巢噁性腫瘤風險模型
인부고단백HE4%CA125항원%악성란소암%란소악성종류풍험모형
Human epididymis protein 4%C125 antigen%Ovarian cancer%Ovarian cancer risk model
目的：研究血清CA125、HE4检测及ROMA模型在恶性卵巢癌诊断中的作用。方法将204例盆腔包块待查患者按照病理学检查结果分为卵巢良性病变组和恶性卵巢癌组，并选取140例健康女性作为对照组，检测所有入选女性的CA125、HE4水平，并计算ROMA值。结果恶性卵巢癌组患者CA125、HE4水平分别为（478．53±930．42） U／ml、（228．02±374．24）pmol／L，卵巢良性病变组分别为（50．64±62．04）U／ml、（37．42±9．28）pmol／L。恶性卵巢癌组患者CA125、HE4水平均明显高于卵巢良性病变组，有显著性差异（ P＜0．05）。但卵巢良性病变组与对照组CA125、HE4水平比较无明显差异（ P＞0．05）。未绝经患者上皮性卵巢癌的高风险性ROMA值≥5．6％，低风险性ROMA值＜5．6％；绝经患者上皮性卵巢癌的高风险性ROMA值≥17．5％，低风险性ROMA值＜17．50％。未绝经组灵敏度、特异性、阳性预测值、阴性预测值分别为59．12％、74．68％、35．04％、88．73％，绝经组分别为58．27％、71．43％、95．52％、14．26％，总灵敏度、特异性、阳性预测值、阴性预测值分别为58．51％、74．49％、67．88％、66．05％。结论血清HE4和CA125检测及ROMA模型，对评估恶性卵巢癌风险具有较高的临床价值，有利于恶性卵巢癌的早期发现、早期诊断及早期治疗。
目的：研究血清CA125、HE4檢測及ROMA模型在噁性卵巢癌診斷中的作用。方法將204例盆腔包塊待查患者按照病理學檢查結果分為卵巢良性病變組和噁性卵巢癌組，併選取140例健康女性作為對照組，檢測所有入選女性的CA125、HE4水平，併計算ROMA值。結果噁性卵巢癌組患者CA125、HE4水平分彆為（478．53±930．42） U／ml、（228．02±374．24）pmol／L，卵巢良性病變組分彆為（50．64±62．04）U／ml、（37．42±9．28）pmol／L。噁性卵巢癌組患者CA125、HE4水平均明顯高于卵巢良性病變組，有顯著性差異（ P＜0．05）。但卵巢良性病變組與對照組CA125、HE4水平比較無明顯差異（ P＞0．05）。未絕經患者上皮性卵巢癌的高風險性ROMA值≥5．6％，低風險性ROMA值＜5．6％；絕經患者上皮性卵巢癌的高風險性ROMA值≥17．5％，低風險性ROMA值＜17．50％。未絕經組靈敏度、特異性、暘性預測值、陰性預測值分彆為59．12％、74．68％、35．04％、88．73％，絕經組分彆為58．27％、71．43％、95．52％、14．26％，總靈敏度、特異性、暘性預測值、陰性預測值分彆為58．51％、74．49％、67．88％、66．05％。結論血清HE4和CA125檢測及ROMA模型，對評估噁性卵巢癌風險具有較高的臨床價值，有利于噁性卵巢癌的早期髮現、早期診斷及早期治療。
목적：연구혈청CA125、HE4검측급ROMA모형재악성란소암진단중적작용。방법장204례분강포괴대사환자안조병이학검사결과분위란소량성병변조화악성란소암조，병선취140례건강녀성작위대조조，검측소유입선녀성적CA125、HE4수평，병계산ROMA치。결과악성란소암조환자CA125、HE4수평분별위（478．53±930．42） U／ml、（228．02±374．24）pmol／L，란소량성병변조분별위（50．64±62．04）U／ml、（37．42±9．28）pmol／L。악성란소암조환자CA125、HE4수평균명현고우란소량성병변조，유현저성차이（ P＜0．05）。단란소량성병변조여대조조CA125、HE4수평비교무명현차이（ P＞0．05）。미절경환자상피성란소암적고풍험성ROMA치≥5．6％，저풍험성ROMA치＜5．6％；절경환자상피성란소암적고풍험성ROMA치≥17．5％，저풍험성ROMA치＜17．50％。미절경조령민도、특이성、양성예측치、음성예측치분별위59．12％、74．68％、35．04％、88．73％，절경조분별위58．27％、71．43％、95．52％、14．26％，총령민도、특이성、양성예측치、음성예측치분별위58．51％、74．49％、67．88％、66．05％。결론혈청HE4화CA125검측급ROMA모형，대평고악성란소암풍험구유교고적림상개치，유리우악성란소암적조기발현、조기진단급조기치료。
Objective To study the role of serum CA125,HE4 detection and ROMA model in the diagnosis of malignant ovarian carcinoma.Methods 204 patients with gynecological pelvic mass in the treatment of surgical operation were selected, and patients were divided into the benign group and the malignant ovarian cancer group in accordance with the pathological exami-nation results,and 140 healthy women were selected as the control group,CA125,HE4 level,and the calculation of ROMA value were tested.Results CA125 and HE4 level in the malignant ovarian cancer group were (478.53 ±930.42) U/ml and (228.02 ±374.24) pmol/L,and those of the benign group were respectively (50.64 ±62.04) U/ml,(37.42 ±9.28) pmol/L.CA125, HE4 level in the malignant ovarian cancer group were significantly higher than those of the benign group,there was significant difference (P<0.05).But CA125 and HE4 level between the benign group and control group had no obvious difference (P>0.05).Premenopausal patients with epithelial ovarian cancer high risk ROMA≥5.6%,low risk of ROMA<5.6%;postmenopa-usal patients with epithelial ovarian cancer high risk ROMA≥17.5%,low risk of ROMA<17.50%.Premenopause group sensi-tivity,specificity,positive predictive value,and negative predictive value were 59.12%,74.68%,35.04%,88.73%,and those of the postmenopausal group were respectively 58.27%,71.43%,95.52%,14.26%,the sensitivity,specificity,positive predictive value,and negative predictive value of the total were respectively 58.51%,74.49%,67.88%,66.05%.Conclusion The serum HE4 and CA125 detection and ROMA model has clinical value in the diagnosis of malignant ovarian carcinoma,it helps early dis-covery,early diagnosis and early treatment of malignant ovarian cancer.
